Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months
... 18% 498 11% (1) Alliance revenue reflects revenue to Wyeth derived from sales of Enbrel (in the United States and Canada), altace and the CYPHER stent. Enbrel(R) continued to post strong revenue growth during the 2007 third quarter. Wyeth has exclusive rights to Enbrel outside o...US Court Rules Against Lupin in Ramipril Patent Case
...rt for the Eastern District of Virginia has issued an opinion following the completion of a trial on Sanofi-Aventis US Patent No - 5061722 relating to altace (Ramipril) drug and found the patent to be valid. Lupin Managing Director Kamal Sharma said, "It was a very close call for us and we are disappoi...Hypertension drugs could lower Disability
... research must be confirmed in future clinical trials. The Food and Drug Administration has approved such ACE inhibitors as Accupril, Captopril, altace and Vasotec. The retrospective study at Hokins, published in the medical journal The Lancet, involved analysis of three years of data from 1995 to 199...Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
... 8% 684 10% (1) Alliance revenue reflects revenue to Wyeth derived from sales of Enbrel (in the United States and Canada), altace and the CYPHER stent. Product Highlights Enbrel(R) continued to post strong revenue growth during 2007. Enbrel sales in the United States and Can...